Menu Close
Video 4 - The rheumatologist-patient biosimilar biologic transition conversation
Video 4 - The rheumatologist-patient biosimilar biologic transition conversation

Prior to transitioning, both rheumatologists and their patients must be fully informed about the policy requiring the transition and have all available information about the biosimilar, such as details about safety and efficacy, the reimbursement policy, patient program information, including contact names and phone numbers. Having this information can also ensure patients and rheumatologists have an informed and constructive conversation about why a patient’s treatment is being changed.

During the first conversations about transitioning to a biosimilar, the way in which rheumatologists and other healthcare providers communicate with patients is key to ensuring a patient’s positive expectations and a smooth transition to the new treatment.

In this video, we present an example of a positive rheumatologist-patient biosimilars transition conversation.

About the Biosimilars•Exchange

ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealthTM information and programs.

This site complies with the HONcode standard for trustworthy health information: verify here.

Arthritis Consumer Experts
© 2000-2021

ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealthTM information and programs.

This site complies with the HONcode standard for trustworthy health information: verify here.

Arthritis Consumer Experts
© 2000-2021

ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealthTM information and programs.

This site complies with the HONcode standard for trustworthy health information: verify here.